HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BAY 1143269

an inhibitor of MAP kinase-interacting kinase 1 (MNK1)

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - BAY 1143269: 1
  - Pyridazines: 11
    - BAY 1143269: 1

Experts

1.	Bergemann, Linda: 1 article (01/2017)
2.	Bömer, Ulf: 1 article (01/2017)
3.	Eis, Knut: 1 article (01/2017)
4.	Lange, Claudia: 1 article (01/2017)
5.	Lienau, Philip: 1 article (01/2017)
6.	Michels, Martin: 1 article (01/2017)
7.	Mumberg, Dominik: 1 article (01/2017)
8.	Petersen, Kirstin: 1 article (01/2017)
9.	Pühler, Florian: 1 article (01/2017)
10.	Santag, Susann: 1 article (01/2017)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2017 - "In summary, the inhibition of MNK1 activity with a highly potent and selective inhibitor BAY 1143269 may provide an innovative approach for anti-cancer therapy." 01/01/2017 - "In addition, BAY 1143269 demonstrated strong efficacy in monotherapy in cell line and patient-derived non-small cell lung cancer xenograft models as well as delayed tumor regrowth in combination treatment with standard of care chemotherapeutics. " 01/01/2017 - "BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity."
2.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/2017 - "In addition, BAY 1143269 demonstrated strong efficacy in monotherapy in cell line and patient-derived non-small cell lung cancer xenograft models as well as delayed tumor regrowth in combination treatment with standard of care chemotherapeutics. "

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Therapeutics